Abstract Details

Title Miller Fischer Syndrome after Vaccination in the United States: A CDC/FDA Vaccine Adverse Event Reporting System Study, 1999-2017

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-021

Objective Objective: To investigate the correlation between Miller Fischer Syndrome and vaccination in adults.

Background Miller Fischer syndrome, considered to be variant of GBS with the clinical feature of ophthalmoplegia, areflexia, and ataxia has been reported after vaccination. There have been multiple case reports of miller Fischer syndrome post vaccination. The study asks the basic question of what's the association of vaccination and Miller Fischer syndrome and what the risk period after receiving the vaccination.

Design/Methods Method: Using data from the Vaccine Adverse Event Reporting System (VAERS) database for the 1999-2017 period, we identified cases of Miller Fischer Syndrome and characterized their temporal relationship with the different vaccination. The initial 6 weeks after vaccination was defined as the risk period for possible cause-effect between vaccination and MFS, while the subsequent 6 weeks were defined as the control period. The only case-centered analysis was utilized.

Results Results: There were 87 cases of MFS (mean age in years 45, male 61%) reported following influenza, hepatitis AB and HPV4 vaccination between 1999 and 2017. The reporting rate of post-vaccination MFS was 0.36 to 0.47 cases per million, which is within the range expected for the general population. Of these cases, 76% were reported within six weeks after vaccination, with 24% of those reported in the first two weeks. Case-centered analyses demonstrated that 76.1% of cases of MFS cases were reported within the risk period.

Conclusions Although we did not observe an increase in the incidence of MFS after vaccination as compared to the general population, the unbalanced distribution of cases within the first 6 weeks is unlikely to be coincidental. Furthermore, case-centered analyses demonstrated that the majority of MFS cases were reported within the six-week risk period. These results warrant the implementation of active surveillance and careful evaluation of patients with signs and symptoms of MFS following vaccination

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Kevin Nolasco	Kevin Nolasco has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��